Franklin Resources Inc. Grows Stock Holdings in ADMA Biologics, Inc. (NASDAQ:ADMA)

Franklin Resources Inc. lifted its stake in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 95.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 327,011 shares of the biotechnology company's stock after acquiring an additional 159,367 shares during the period. Franklin Resources Inc. owned approximately 0.14% of ADMA Biologics worth $5,608,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in ADMA. Alliancebernstein L.P. boosted its stake in ADMA Biologics by 13.6% in the 4th quarter. Alliancebernstein L.P. now owns 275,263 shares of the biotechnology company's stock worth $4,721,000 after purchasing an additional 32,923 shares during the period. CIBC Private Wealth Group LLC lifted its holdings in shares of ADMA Biologics by 137.1% in the fourth quarter. CIBC Private Wealth Group LLC now owns 5,108 shares of the biotechnology company's stock worth $95,000 after buying an additional 2,954 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its position in shares of ADMA Biologics by 57.9% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 2,762,700 shares of the biotechnology company's stock valued at $47,380,000 after acquiring an additional 1,013,456 shares during the period. Pictet Asset Management Holding SA grew its stake in ADMA Biologics by 10.5% during the fourth quarter. Pictet Asset Management Holding SA now owns 30,885 shares of the biotechnology company's stock valued at $530,000 after acquiring an additional 2,928 shares in the last quarter. Finally, New Age Alpha Advisors LLC bought a new stake in ADMA Biologics during the 4th quarter worth approximately $221,000. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald reissued an "overweight" rating and issued a $25.00 price target on shares of ADMA Biologics in a report on Tuesday, March 4th.

ADMA Biologics Price Performance

Shares of ADMA stock traded up $0.90 during trading on Tuesday, hitting $21.81. The company had a trading volume of 4,788,683 shares, compared to its average volume of 3,580,892. The stock's 50-day moving average is $17.86 and its two-hundred day moving average is $18.16. The stock has a market capitalization of $5.16 billion, a price-to-earnings ratio of 77.89 and a beta of 0.53. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. ADMA Biologics, Inc. has a 52 week low of $5.91 and a 52 week high of $23.64.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.